+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vasculitis Treatment Market by Treatment Type (Biologics, Corticosteroids, Immunosuppressants), Disease Type (ANCA Associated Vasculitis, Behcet Disease, Giant Cell Arteritis), Administration Route, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Vasculitis Treatment Market by Treatment Type (Biologics, Corticosteroids, Immunosuppressants), Disease Type (ANCA Associated Vasculitis, Behcet Disease, Giant Cell Arteritis), Administration Route, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Vasculitis Treatment Market by Treatment Type (Biologics, Corticosteroids, Immunosuppressants), Disease Type (ANCA Associated Vasculitis, Behcet Disease, Giant Cell Arteritis), Administration Route, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888985
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The vasculitis treatment market is undergoing significant transformation as targeted therapies, innovative drug technologies, and shifting regulatory frameworks shape future clinical outcomes. Senior decision-makers face evolving challenges and opportunities as integrated care and advanced manufacturing redefine how vasculitis is managed worldwide.

Market Snapshot: Vasculitis Treatment Market Overview

The Vasculitis Treatment Market grew from USD 202.92 million in 2024 to USD 213.64 million in 2025. It is expected to continue growing at a CAGR of 5.23%, reaching USD 275.68 million by 2030. This expansion reflects not only rising global awareness and earlier diagnosis but also accelerating adoption of biologics and precision medicine approaches. Pharmaceutical and biotech companies are increasing investments to meet growing clinical demands, while evolving reimbursement and regulatory conditions further shape development strategies.

Scope & Segmentation

This comprehensive analysis covers critical facets of the Vasculitis Treatment Market, providing future-focused insights for strategy and investment decisions. Key segmentation areas include:

  • Treatment Types: Biologics (Rituximab; Tumor Necrosis Factor Inhibitors: Adalimumab, Etanercept, Infliximab); Corticosteroids; Immunosuppressants (Azathioprine, Cyclophosphamide, Methotrexate, Mycophenolate Mofetil); Plasma Exchange.
  • Disease Types: ANCA Associated Vasculitis, Behcet Disease, Giant Cell Arteritis, IgA Vasculitis, Takayasu Arteritis.
  • Administration Routes: Intravenous, Oral, Subcutaneous.
  • End Users: Ambulatory Care Centers, Clinics, Hospitals, Specialty Centers.
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.
  • Geographies: Americas (including United States, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (spanning major economies and emerging healthcare markets); Asia-Pacific (including China, India, Japan, Australia, South Korea, and Southeast Asia).
  • Leading Companies: F. Hoffmann-La Roche Ltd, ChemoCentryx, Inc., AbbVie Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Amgen Inc., UCB S.A., Novartis AG, Pfizer Inc., Sanofi S.A.

Key Takeaways for Senior Decision-Makers

  • Patient-centric and precision medicine solutions drive current innovation, with biologics and immunomodulators gaining traction for refractory and complex vasculitic cases.
  • Market access strategies require proactive navigation of an evolving regulatory environment and diverse reimbursement models, particularly as real-world evidence and outcome-based contracts become more prevalent.
  • Segmentation by disease type and administration route remains vital, as sub-populations respond variably to biologics, immunosuppressants, and plasma exchange.
  • Regional market differences remain pronounced, with US and European markets prioritizing rapid adoption of targeted therapies and digital health tools, while emerging regions focus on infrastructure, local manufacturing, and regulatory alignment.
  • Strategic alliances—across academia, biotechs, and contract development—are accelerating novel therapy development and scaling advanced biologics manufacturing.
  • Integrated supply chain strategies and investment in domestic manufacturing are increasingly important for operational resilience, particularly in light of changing tariff and trade policies.

Tariff Impact on Accessibility and Cost Structure

Adjusted tariff regimes scheduled for implementation in the United States from 2025 are anticipated to cause shifts in procurement strategies and medication pricing. Increased duties on pharmaceutical imports could impact manufacturers' supply chains, procurement budgets for health systems, and cash flow for biotechs relying on foreign contract manufacturing. To address these challenges, stakeholders are evaluating domestic production, renegotiating trade agreements, and engaging in risk-sharing reimbursement arrangements to protect patient access.

Methodology & Data Sources

This report draws on a multiphase methodology combining thorough literature reviews, regulatory documentation, clinical registry data, and direct interviews with clinicians, payers, and industry experts. Quantitative and qualitative insights are rigorously validated through triangulation and quality assurance measures, ensuring actionable intelligence and high data integrity across market estimates and forecasts.

Why This Report Matters

  • Enables evidence-based portfolio planning and investment prioritization through in-depth, segmented insights by treatment type, region, and end user.
  • Equips executive teams with clarity on technology adoption trends, risk factors, and policy shifts affecting global vasculitis care delivery.
  • Informs negotiations and collaboration frameworks by benchmarking leading players, pipeline assets, and regional best practices.

Conclusion

The Vasculitis Treatment Market offers new opportunities as the adoption of tailored therapies, digital health, and local manufacturing increases. A strategic focus on collaboration and regulatory alignment will position stakeholders for sustainable success and clinical impact in the evolving landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging clinical trial data supporting precision-based biologics for ANCA-associated vasculitis
5.2. Integration of digital health platforms for remote monitoring of vasculitis treatment response
5.3. Shift toward steroid-sparing regimens using JAK inhibitors in chronic vasculitis patient management
5.4. Advances in biomarker-driven diagnosis enabling personalized treatment pathways for vasculitis
5.5. Growing pipeline of cell-based therapies targeting refractory large vessel vasculitis subtypes
5.6. Strategic partnerships between biotech companies and academic centers accelerating vasculitis R&D initiatives
5.7. Regulatory approval trends for new orphan drugs and fast-track designations in rare vasculitis indications
5.8. Rising emphasis on patient-reported outcomes and quality-of-life metrics in vasculitis clinical trials
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Vasculitis Treatment Market, by Treatment Type
8.1. Introduction
8.2. Biologics
8.2.1. Rituximab
8.2.2. Tumor Necrosis Factor Inhibitors
8.2.2.1. Adalimumab
8.2.2.2. Etanercept
8.2.2.3. Infliximab
8.3. Corticosteroids
8.4. Immunosuppressants
8.4.1. Azathioprine
8.4.2. Cyclophosphamide
8.4.3. Methotrexate
8.4.4. Mycophenolate Mofetil
8.5. Plasma Exchange
9. Vasculitis Treatment Market, by Disease Type
9.1. Introduction
9.2. ANCA Associated Vasculitis
9.3. Behcet Disease
9.4. Giant Cell Arteritis
9.5. IgA Vasculitis
9.6. Takayasu Arteritis
10. Vasculitis Treatment Market, by Administration Route
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Vasculitis Treatment Market, by End User
11.1. Introduction
11.2. Ambulatory Care Centers
11.3. Clinics
11.4. Hospitals
11.5. Specialty Centers
12. Vasculitis Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Vasculitis Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Vasculitis Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Vasculitis Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. ChemoCentryx, Inc.
16.3.3. AbbVie Inc.
16.3.4. Johnson & Johnson
16.3.5. Bristol-Myers Squibb Company
16.3.6. Amgen Inc.
16.3.7. UCB S.A.
16.3.8. Novartis AG
16.3.9. Pfizer Inc.
16.3.10. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. VASCULITIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL VASCULITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. VASCULITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. VASCULITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. VASCULITIS TREATMENT MARKET: RESEARCHAI
FIGURE 26. VASCULITIS TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 27. VASCULITIS TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 28. VASCULITIS TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. VASCULITIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VASCULITIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL VASCULITIS TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADALIMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ETANERCEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY INFLIXIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY METHOTREXATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ANCA ASSOCIATED VASCULITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ANCA ASSOCIATED VASCULITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BEHCET DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BEHCET DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY GIANT CELL ARTERITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY GIANT CELL ARTERITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IGA VASCULITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IGA VASCULITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TAKAYASU ARTERITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TAKAYASU ARTERITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 117. CANADA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 118. CANADA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 119. CANADA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 120. CANADA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 121. CANADA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 122. CANADA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 123. CANADA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 124. CANADA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 125. CANADA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 126. CANADA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 127. CANADA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 128. CANADA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 129. CANADA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. CANADA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. CANADA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. CANADA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 134. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 135. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 136. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 137. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 138. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 139. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 140. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 141. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 142. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 143. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 144. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 145. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. MEXICO VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 216. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 217. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 218. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 219. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 222. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 223. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 224. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 225. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 226. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 227. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. GERMANY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 232. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 233. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 234. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 235. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 236. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 237. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 238. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 239. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 240. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 241. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 242. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 243. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. FRANCE VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 253. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 254. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. ITALY VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 264. ITALY VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 265. ITALY VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 266. ITALY VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 267. ITALY VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 268. ITALY VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 269. ITALY VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 270. ITALY VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 271. ITALY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 272. ITALY VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 273. ITALY VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 274. ITALY VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 275. ITALY VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. ITALY VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. ITALY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. ITALY VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 280. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 281. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 282. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 283. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 284. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 285. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 286. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 287. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 288. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 289. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 290. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 291. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. SPAIN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 314. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2024 (USD MILLION)
TABLE 316. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2025-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 318. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 320. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 322. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 323. SAUDI ARABIA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 324. SAUDI ARABIA VASCULIT

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Vasculitis Treatment market report include:
  • F. Hoffmann-La Roche Ltd
  • ChemoCentryx, Inc.
  • AbbVie Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • UCB S.A.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 213.64 Million
Forecasted Market Value ( USD ) by 2030 $ 275.68 Million
Compound Annual Growth Rate5.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Vasculitis Market - Product Image

Vasculitis Market

  • Report
  • 250 Pages
  • Global
From
Vasculitis Treatment - Global Strategic Business Report - Product Image

Vasculitis Treatment - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
Immunoglobulin A IgA Vasculitis Global Market Report 2025 - Product Image

Immunoglobulin A IgA Vasculitis Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035 - Product Image

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Vasculitis Drug Pipeline Analysis Report 2025 - Product Image

Vasculitis Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From

About the Vasculitis Drug Market

Vasculitis is a group of diseases that cause inflammation of the blood vessels. It can affect any organ in the body, but is most commonly seen in the heart, lungs, and kidneys. Vasculitis drugs are used to treat the inflammation and reduce the risk of organ damage. These drugs are typically immunosuppressants, which work by suppressing the immune system and reducing inflammation. Common vasculitis drugs include corticosteroids, cyclophosphamide, and methotrexate. In addition to these drugs, there are also biologic agents, such as rituximab and tocilizumab, which are used to treat more severe cases of vasculitis. These drugs are designed to target specific parts of the immune system, and are often used in combination with other treatments. The vasculitis drug market is an important part of the cardiovascular drug market, as it provides treatments for a wide range of conditions. Companies in this market include Pfizer, Merck, AbbVie, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.